Ribonucleic acid-based therapy for autoimmune diabetes: LncRNA MEG3 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 21/March/2019, 8.49  am